<?xml version="1.0" ?>
<!DOCTYPE pmc-articleset PUBLIC "-//NLM//DTD ARTICLE SET 2.0//EN" "https://dtd.nlm.nih.gov/ncbi/pmc/articleset/nlm-articleset-2.0.dtd">
<pmc-articleset><article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" article-type="case-report">
  <?properties open_access?>
  <front>
    <journal-meta>
      <journal-id journal-id-type="nlm-ta">BMC Vet Res</journal-id>
      <journal-id journal-id-type="iso-abbrev">BMC Vet. Res</journal-id>
      <journal-title-group>
        <journal-title>BMC Veterinary Research</journal-title>
      </journal-title-group>
      <issn pub-type="epub">1746-6148</issn>
      <publisher>
        <publisher-name>BioMed Central</publisher-name>
        <publisher-loc>London</publisher-loc>
      </publisher>
    </journal-meta>
    <article-meta>
      <article-id pub-id-type="pmid">26265349</article-id>
      <article-id pub-id-type="pmc">4534110</article-id>
      <article-id pub-id-type="publisher-id">478</article-id>
      <article-id pub-id-type="doi">10.1186/s12917-015-0478-6</article-id>
      <article-categories>
        <subj-group subj-group-type="heading">
          <subject>Case Report</subject>
        </subj-group>
      </article-categories>
      <title-group>
        <article-title>Anaphylactoid reaction caused by sodium ceftriaxone in two horses experimentally infected by <italic>Borrelia burgdorferi</italic></article-title>
      </title-group>
      <contrib-group>
        <contrib contrib-type="author" corresp="yes">
          <name>
            <surname>Basile</surname>
            <given-names>Roberta Carvalho</given-names>
          </name>
          <address>
            <email>basile.roberta@gmail.com</email>
          </address>
          <xref ref-type="aff" rid="Aff1"/>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Rivera</surname>
            <given-names>Gabriela Gomes</given-names>
          </name>
          <address>
            <email>gabirivera@gmail.com</email>
          </address>
          <xref ref-type="aff" rid="Aff2"/>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Del Rio</surname>
            <given-names>Lara Antoniassi</given-names>
          </name>
          <address>
            <email>la3barrels@hotmail.com</email>
          </address>
          <xref ref-type="aff" rid="Aff1"/>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>de Bonis</surname>
            <given-names>Talissa Camargo Mantovani</given-names>
          </name>
          <address>
            <email>talissadebonis@hotmail.com</email>
          </address>
          <xref ref-type="aff" rid="Aff1"/>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>do Amaral</surname>
            <given-names>Gabriel Paiva Domingues</given-names>
          </name>
          <address>
            <email>gabrielwestern1@hotmail.com</email>
          </address>
          <xref ref-type="aff" rid="Aff1"/>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Giangrecco</surname>
            <given-names>Edson</given-names>
          </name>
          <address>
            <email>edsonhv@fcav.unesp.br</email>
          </address>
          <xref ref-type="aff" rid="Aff2"/>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Ferraz</surname>
            <given-names>Guilherme</given-names>
          </name>
          <address>
            <email>gferraz@fcav.unesp.br</email>
          </address>
          <xref ref-type="aff" rid="Aff1"/>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Yoshinari</surname>
            <given-names>Natalino Hajime</given-names>
          </name>
          <address>
            <email>natayoshinari@gmail.com</email>
          </address>
          <xref ref-type="aff" rid="Aff3"/>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Canola</surname>
            <given-names>Paulo Al&#xE9;scio</given-names>
          </name>
          <address>
            <email>pacanola@fcav.unesp.br</email>
          </address>
          <xref ref-type="aff" rid="Aff2"/>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Queiroz Neto</surname>
            <given-names>Antonio</given-names>
          </name>
          <address>
            <email>aqueiroz@fcav.unesp.br</email>
          </address>
          <xref ref-type="aff" rid="Aff1"/>
        </contrib>
        <aff id="Aff1"><label/>Faculdade de Ci&#xEA;ncias Agr&#xE1;rias e Veterin&#xE1;rias, UNESP &#x2013; Univ Estadual Paulista, Campus Jaboticabal, Departamento de Morfologia e Fisiologia Animal, Laborat&#xF3;rio de Farmacologia e Fisiologia do Exerc&#xED;cio Equino (LAFEQ), Jaboticabal, SP 14884-900 Brazil </aff>
        <aff id="Aff2"><label/>Departamento de Cl&#xED;nica e Cirurgia Veterin&#xE1;ria, Jaboticabal, Brazil </aff>
        <aff id="Aff3"><label/>Faculdade de Medicina da Universidade de S&#xE3;o Paulo FMUSP, Departamento de Reumatologia, S&#xE3;o Paulo, Brazil </aff>
      </contrib-group>
      <pub-date pub-type="epub">
        <day>12</day>
        <month>8</month>
        <year>2015</year>
      </pub-date>
      <pub-date pub-type="pmc-release">
        <day>12</day>
        <month>8</month>
        <year>2015</year>
      </pub-date>
      <pub-date pub-type="collection">
        <year>2015</year>
      </pub-date>
      <volume>11</volume>
      <elocation-id>197</elocation-id>
      <history>
        <date date-type="received">
          <day>24</day>
          <month>9</month>
          <year>2014</year>
        </date>
        <date date-type="accepted">
          <day>13</day>
          <month>7</month>
          <year>2015</year>
        </date>
      </history>
      <permissions>
        <copyright-statement>&#xA9; Basile et al. 2015</copyright-statement>
        <license license-type="OpenAccess">
          <license-p>
<bold>Open Access</bold> This article is distributed under the terms of the Creative Commons Attribution 4.0 International License (<ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/licenses/by/4.0/">http://creativecommons.org/licenses/by/4.0/</ext-link>), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (<ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/publicdomain/zero/1.0/">http://creativecommons.org/publicdomain/zero/1.0/</ext-link>) applies to the data made available in this article, unless otherwise stated.</license-p>
        </license>
      </permissions>
      <abstract id="Abs1">
        <sec>
          <title>Background</title>
          <p>Lyme borreliosis is a disease transmitted by ticks to mammals, especially in horses and humans. Caused by a spirochete <italic>Borrelia burgdorferi</italic>, it can result in lameness, arthritis, carditis, dermatitis and neurological signs. Anaphylactoid reactions are severe responses caused by direct action of substances (drugs, toxins), which can pose risks to life. Still poorly documented in horses, these reactions are caused by the effects of inflammatory mediators such as histamine, kinins and arachidonic acid metabolites. The last two are the most clinically relevant for the species.</p>
        </sec>
        <sec>
          <title>Case presentation</title>
          <p>The simultaneous occurrence of anaphylactoid reaction in two horses experimentally infected by <italic>Borrelia burgdorferi</italic> undergoing intravenous treatment with ceftriaxone sodium is reported. It was administered 4.7 &#xD7; 10<sup>8</sup> spirochetes intradermal and subcutaneous applications in both horses to evaluate clinical aspects of the Lyme disease, 95 days before the application of sodium ceftriaxone. During the administration, one horse (a gelding) showed immediate and severe anaphylactoid symptoms such as urticaria, dyspnea, tachycardia, and eyelid edema, which were controlled by injecting dexamethasone. After 1 day, it expressed signs of abdominal discomfort, caused by severe bloat, which was treated surgically via celiotomy. Subsequently, this gelding had piroplasmosis and severe anemia, requiring treatment with an antimicrobial and blood transfusion. Second horse (a mare) showed signs of hypotension during the application of the antibiotic, which disappeared only when the application was interrupted. Days after the event, the mare developed moderate large colon bloat, which was treated with medication only. Subsequently the mare was evolved into the prodromal phase of laminitis in one of the forelimbs, which was treated for 10&#xA0;days with non-steroidal anti-inflammatory and rheology modifying drugs and cryotherapy.</p>
        </sec>
        <sec>
          <title>Conclusions</title>
          <p>From the two cases presented here, it does appear that sodium ceftriaxone can induce anaphylactoid reactions in horses infected by <italic>Borrelia burgdorferi</italic>, which may evolve into colic syndrome, laminitis and the occurrence of opportunistic infections. However, further evidence should be collected in order to draw definite conclusions.</p>
        </sec>
      </abstract>
      <kwd-group xml:lang="en">
        <title>Keywords</title>
        <kwd>Hypersensitivity</kwd>
        <kwd>Lyme</kwd>
        <kwd>Colic</kwd>
        <kwd>Laminitis</kwd>
      </kwd-group>
      <custom-meta-group>
        <custom-meta>
          <meta-name>issue-copyright-statement</meta-name>
          <meta-value>&#xA9; The Author(s) 2015</meta-value>
        </custom-meta>
      </custom-meta-group>
    </article-meta>
  </front>
  <body>
    <sec id="Sec1">
      <title>Background</title>
      <p>Lyme borreliosis is a multisystemic disease that affects humans, domestic and wild animals, transmitted by ticks and caused by spirochete <italic>Borrelia burgdorferi</italic> sensu lato. In horses, were necessary at least 18&#xA0;h of tick attachment to transmission of the bacteria to the host, which can present lameness, arthritis, uveitis, encephalitis, abortion, foal mortality and recurrent hemoparasites infections. The treatment can be conducted using tetracycline, doxycycline or ceftiofur [<xref ref-type="bibr" rid="CR1">1</xref>]. Conducting sodium ceftriaxone therapy for borreliosis has been reported only in humans [<xref ref-type="bibr" rid="CR2">2</xref>]. Anaphylaxis is the most severe form of allergic reaction called Type 1 hypersensitivity, and occurs in horses mainly in response to toxins from venomous animals, drugs and food allergens [<xref ref-type="bibr" rid="CR3">3</xref>]. The classical anaphylactic reaction is caused by the IgE antibodies binding onto the surface of mast cells and basophils with subsequent release of inflammatory mediators [<xref ref-type="bibr" rid="CR3">3</xref>&#x2013;<xref ref-type="bibr" rid="CR6">6</xref>]. Anaphylactoid reactions are symptomatically similar, but they are caused by direct action of toxic substances (e.g. endotoxins, certain drugs and chemicals) with the subject has not necessarily been previously &#x201C;sensitized&#x201D; [<xref ref-type="bibr" rid="CR5">5</xref>]. They do not involve IgE participation and occur through a direct nonimmune-mediated release of the same mediators [<xref ref-type="bibr" rid="CR7">7</xref>]. The main mediators of a reaction are biogenic amines (histamine, serotonin, catecholamines), vasoactive polypeptides (kinins, cationic proteins, complement system anaphylaxins C<sub>3A</sub>, C<sub>5A</sub>, C<sub>567</sub>), lysosomal enzymes, vasoactive lipids (prostaglandins, endoperoxides, thromboxanes), phospholipids (platelet activating factor) and chemotactic substances [<xref ref-type="bibr" rid="CR5">5</xref>, <xref ref-type="bibr" rid="CR6">6</xref>]. Anaphylactoid reactions are difficult to be reproduced experimentally, however there are reports of anaphylaxis induction experiments in horses by sensitization with bovine serum [<xref ref-type="bibr" rid="CR8">8</xref>] that were conducted on 20 adult ponies under anesthesia. Cardiovascular, respiratory, hematological, electrolyte and biochemical responses were evaluated during the acute phase. The results contributed significantly to describing the cascade of events that occur during anaphylaxis in the species. The authors reported that the first event occurred about 2&#xA0;min after contact with the antigen. Blood pressure (common carotid artery) decreased significantly while pulmonary artery pressure increased and the pressure of the abdominal vena cava decreased slightly. During anaphylaxis, there was hemoconcentration, leukopenia, thrombocytopenia, and hyperkalemia. Initially, plasma concentrations of histamine and bradykinin increased significantly (more than four times). Clinically, tachypnea and tachycardia were also observed, which returned to normal in about 12&#xA0;min. The therapeutic response of 16 ponies with induced anaphylaxis to antagonistic drugs of the main anaphylactic mediators [<xref ref-type="bibr" rid="CR9">9</xref>] has also been evaluated. The author compared the antagonist effects of burimamide and tripelennamine on histamine and also evaluated methysergide as serotonin blocker. The efficacy of meclofenamate sodium, and acetylsalicylic acid as non steroidal anti-inflammatory drugs was evaluated, as well. The results show that meclofenamate sodium and acetylsalicylic acid effectively inhibited and managed the anaphylactic cardiovascular and respiratory symptoms, suggesting that in horses, prostaglandins, thromboxanes and kinins have greater clinical relevance to immediate hypersensitivity [<xref ref-type="bibr" rid="CR6">6</xref>]. On the other hand, histamine is primarily responsible for most adverse events in humans and dogs [<xref ref-type="bibr" rid="CR4">4</xref>]. There are few case reports in the literature about anaphylaxis and anaphylactoid reactions in horses. There is a case description of a gelding that received intravenous ivermectin and developed a lethal anaphylactic reaction [<xref ref-type="bibr" rid="CR10">10</xref>]. More recently, there is an unusual case of anaphylaxis in a neonatal foal caused by inadvertent intravenous administration of breast milk [<xref ref-type="bibr" rid="CR11">11</xref>], which was reversed with epinephrine, and dexamethasone, and intensive outpatient treatment for 9 days. The most recent publications on IgE-mediated hypersensitivity in horses emphasize only dermatological aspects as signs of atopy, allergy to insect stings, food and parasitism associated allergies [<xref ref-type="bibr" rid="CR12">12</xref>, <xref ref-type="bibr" rid="CR13">13</xref>]. Sodium Ceftriaxone, classified as third-generation cephalosporin, is a broad spectrum antibiotic with a beta lactam ring in its structure and capable of bypassing the blood-brain barrier [<xref ref-type="bibr" rid="CR14">14</xref>]. Its pharmacokinetics has been evaluated in mares [<xref ref-type="bibr" rid="CR15">15</xref>], adult horses [<xref ref-type="bibr" rid="CR16">16</xref>] and foals [<xref ref-type="bibr" rid="CR17">17</xref>]. These studies were performed by intravenously injecting a single dose between 25 and 50&#xA0;mg/kg, diluted in saline solution. No adverse drug reactions have been reported in these studies. To date, there are no reports regarding the occurrence of adverse reactions to ceftriaxone sodium in horses, as has already been observed in humans [<xref ref-type="bibr" rid="CR16">16</xref>]. Therefore, this case report describes the occurrence of non-fatal anaphylactic reaction in two horses after intravenous administration of ceftriaxone sodium, the immediate clinical outcome, consequences and subsequent therapeutic strategies adopted.</p>
    </sec>
    <sec id="Sec2">
      <title>Case presentation</title>
      <p>Two sound horses, a gelding and a mare chosen from the group of experimental horses of the University, approximately eight years old, were experimentally infected with <italic>Borrelia burgdorferi</italic>, using a dose of 4.7 &#xD7; 10<sup>8</sup> bacteria per horse, divided in four simultaneous applications (2 subcutaneous and 2 intradermal), in the region of the superficial cervical lymph nodes, with the approval of the Ethics Committee on Animal Use - CEUA of UNESP (protocol 001968/13). The objective of the experiment was to compare the clinical and laboratorial differences between the infection of <italic>Borrelia burgdorferi</italic> strain G39/40 in horses versus the Borreliosis diagnosed in Brazil in addition to their treatment viability with sodium ceftriaxone, since it is an effective antibiotic to control borreliosis, including its neurological forms [<xref ref-type="bibr" rid="CR13">13</xref>]. There were no previous reports of sodium ceftriaxone adverse reactions in horses. Both horses had only mild acute clinical alterations in the first 14&#xA0;days after infection, characterized by augmented submandibular lymph nodes, pale mucosa, dorsal sensibility and hyporexia. Ninety five days after experimental infection, both animals were injected intravenously (4 drops/s) ceftriaxone sodium at the dose of 25&#xA0;mg/kg, diluted in 500&#xA0;ml of sterile 0.9&#xA0;% sodium chloride saline solution, by catheterization<xref ref-type="fn" rid="Fn1">1</xref><sup>,</sup><xref ref-type="fn" rid="Fn2">2</xref> of the left jugular vein. The clinical and hematological parameters of both horses were checked before administration and were within normal range. However, the clinical and hematological parameters changed approximately 2&#xA0;min after the drug was administered. Both horses that received sodium ceftriaxone developed an anaphylactoid reaction. The entire experiment was conducted on only these two animals.</p>
      <sec id="Sec3">
        <title>Case 1: Gelding</title>
        <p>A male purebred Arabian horse weighing 410&#xA0;kg, submitted to 6&#xA0;h of food fasting had a heart rate (HR) of 40&#xA0;bpm, respiratory rate (RR) of 22 mrm, rosy mucous membranes, capillary refill time (CRT) of 2&#xA0;s, rectal temperature (RT) of 37.1&#xA0;&#xB0;C and hematological parameters within the reference range for the species (Table&#xA0;<xref rid="Tab1" ref-type="table">1</xref>, Basal) before the administration of the antibiotic. About 17&#xA0;min into the administration of ceftriaxone sodium (Day 1), after 205&#xA0;mL of the solution had dripped, the horse showed tachycardia (heart rate&#x2009;=&#x2009;96&#xA0;bpm), dyspnea and urticaria on the neck left side (the same side where the drug was being injected). The drug dripping was discontinued immediately, but the animal still presented severe dyspnea. The gelding respiratory function normalized a minute after 0.05&#xA0;mg/kg dexamethasone was injected. A noticeable swelling of eyelids was observed an hour after the allergic event. At this time the patient had a HR of 48&#xA0;bpm, RR of 20 mrm, pale mucosa, RT of 37.7&#xA0;&#xB0;C and a slight reduction of intestinal motility. The horse behavior remained apathetic for the rest of the day, with no significant changes upon physical examination and was fed only hay. On day 2 in the morning, the gelding was fed 1.0&#xA0;kg of commercial feed, but due to abdominal discomfort it positioned itself on lateral recumbency. Upon examination, the horse had severe bilateral abdominal distention, a HR of 37&#xA0;bpm, RR 20 mrm, RT 37.2&#xA0;&#xB0;C, pale mucosa, intestinal hypomotility and yellowish and turbid peritoneal fluid. In the laboratory, the peritoneal fluid was characterized by total protein of 96&#xA0;g/dL; pH&#xA0;7.6; density 1.010&#xA0;g/dL and 1250 cells/ml (71&#xA0;% segmented neutrophils, 22&#xA0;% lymphocytes and 7&#xA0;% macrophages). Hematological and blood gas evaluation of venous blood showed anemia and hemoconcentration (Table&#xA0;<xref rid="Tab1" ref-type="table">1</xref>, Day 2), metabolic and respiratory acidosis, hyponatremia, hypokalemia, hypochloremia, hyperglycemia, and a blood lactate concentration (Table&#xA0;<xref rid="Tab2" ref-type="table">2</xref>, Day 2). The abdominal ultrasonography showed severe gaseous distension, <italic>ileus</italic>, along with wall thickening of small intestine (Fig.&#xA0;<xref rid="Fig1" ref-type="fig">1</xref>). The ultrasonography results were consistent with volvulus of the small intestine; therefore, the gelding was referred to the surgical center for exploratory celitomy. Before the surgery, an intravenous antibiotic therapy with 20.000U/kg potassium penicillin<xref ref-type="fn" rid="Fn3">3</xref> was initiated. During surgery, were observed gas distention throughout the small bowel, wall edema of the small and large colon, cecum, jejunum and <italic>ileus</italic> (Fig.&#xA0;<xref rid="Fig2" ref-type="fig">2</xref>). There were also retroflexion of the pelvic flexure and displacement of cecum. The small intestine milking was followed by gas aspiration of the cecum, colon repositioning and washing of the abdominal cavity with neomycin diluted in 10&#xA0;% Sodium lactate Ringer's solution. After surgery, the horse recovered uneventful from anesthesia and defecated upon rising. The antibiotic therapy was continued post operatively with penicillin potassium (20,000U/kg), every 8&#xA0;h, for three consecutive days. The patient was also treated with a single dose of both furosemide (0.5&#xA0;mg/kg) and dexamethasone (0.05&#xA0;mg/kg) to reduce the intestinal edema; 30&#xA0;mL of Potassium Chloride (150&#xA0;mg/mL) diluted in 1&#xA0;L of Sodium Lactate Ringer's solution to correct the hypokalemia; 3&#xA0;l of solution of 10&#xA0;% DMSO solution (100&#xA0;mL/L in Ringer's lactate solution), once daily for 2 days; and, flunixin meglumine (0.25&#xA0;mg/kg) once daily for 3 days. The abdominal incision was cleaned using aqueous chlorhexidine solution while repellent was applied around the surgical wound twice a day, for 10&#xA0;days. This patient progressed steadily until the eighteenth day after anaphylaxis, when it showed apathy, loss of appetite, fever of 40.1&#xA0;&#xB0;C, pale mucosa, 3&#xA0;s CRT, HR 72&#xA0;bpm, RR 44 mrm and severe back pain. A blood sample was collected using EDTA tube and sent to the Parasitology Laboratory for Polymerase Chain Reaction (Nested-PCR) to detect the presence of <italic>Babesia caballi</italic> and <italic>Theileria equi</italic>, as well as Real-Time PCR for <italic>Anaplasma phagocytophilum</italic>. The test revealed <italic>Theileria equi</italic> infection. Therefore, intramuscular treatment with imidocarb<xref ref-type="fn" rid="Fn4">4</xref> (4.0&#xA0;mg/kg) was instituted, divided into two daily doses for 2 days, along with Dipyrone (25&#xA0;mg/kg), every 12&#xA0;h for 2 days. Subsequent to treating piroplasmosis, the gelding also revealed high serum concentrations of indirect bilirubin, creatine kinase, gamma glutamyl transferase, globulin and fibrinogen (Table&#xA0;<xref rid="Tab3" ref-type="table">3</xref>, Day 20). On the twentieth day after anaphylactoid reaction, the gelding showed marked hypochromic normocytic anemia and neutrophilia (Table&#xA0;<xref rid="Tab1" ref-type="table">1</xref>, day 20) and the patient was transfused with 6&#xA0;L of whole blood. The following day, the blood parameters improved (Tables&#xA0;<xref rid="Tab1" ref-type="table">1</xref> and <xref rid="Tab3" ref-type="table">3</xref>, Day 21). However, the horse showed signs of abdominal discomfort though sternal recumbence and anorexia with normal intestinal motility, fecal output and consistency, mild tachycardia and depression, suggestive of gastritis. A twenty-day course of omeprazole<xref ref-type="fn" rid="Fn5">5</xref> was instituted and a satisfactory improvement of its clinical and hematological status occurred 28&#xA0;days after the anaphylaxis (Tables&#xA0;<xref rid="Tab1" ref-type="table">1</xref>, <xref rid="Tab2" ref-type="table">2</xref> and <xref rid="Tab3" ref-type="table">3</xref>, Day 28).<table-wrap id="Tab1"><label>Table 1</label><caption><p>Gelding red blood cell count before and after anaphylactic reaction to sodium ceftriaxone, which occurred on day 1</p></caption><table frame="hsides" rules="groups"><thead><tr><th/><th>Basal</th><th>Day 2</th><th>Day 3</th><th>Day 6</th><th>Day 10</th><th>Day 20</th><th>Day 21</th><th>Day 28</th><th>Reference<sup>a</sup>
</th></tr></thead><tbody><tr><td>Erythrocytes x 10<sup>6</sup> [cells/ml]</td><td>8.40</td><td>6.72</td><td>6.10</td><td>6.32</td><td>6.30</td><td>
<italic>3.10</italic>
</td><td>6.20</td><td>6.50</td><td>6.0&#x2013;9.7</td></tr><tr><td>Hemoglobin [g/dL]</td><td>12.5</td><td>10.6</td><td>9.8</td><td>9.8</td><td>9.2</td><td>
<italic>4.2</italic>
</td><td>8.6</td><td>10.0</td><td>8.3&#x2013;14.4</td></tr><tr><td>Hematocrit [%]</td><td>38.0</td><td>
<italic>29.5</italic>
</td><td>
<italic>26.7</italic>
</td><td>
<italic>27.4</italic>
</td><td>
<italic>28.0</italic>
</td><td>
<italic>13.0</italic>
</td><td>
<italic>27.0</italic>
</td><td>30.0</td><td>30&#x2013;44</td></tr><tr><td>MCV [fL]</td><td>45.2</td><td>-</td><td>-</td><td>-</td><td>44.4</td><td>41.9</td><td>43.5</td><td>46.2</td><td>36&#x2013;52.1</td></tr><tr><td>MCH [pg]</td><td>14.9</td><td>-</td><td>-</td><td>-</td><td>14.6</td><td>13.5</td><td>13.9</td><td>15.4</td><td>11.5&#x2013;18.2</td></tr><tr><td>MCHC [g/dL]</td><td>32.9</td><td>-</td><td>-</td><td>-</td><td>32.9</td><td>32.3</td><td>31.9</td><td>33.4</td><td>31.2&#x2013;34.9</td></tr><tr><td>Leucocytes [cells/uL]</td><td>10100</td><td>9800</td><td>12900</td><td>5700</td><td>
<italic>11200</italic>
</td><td>
<italic>10800</italic>
</td><td>
<italic>14800</italic>
</td><td>9500</td><td>6400&#x2013;10600</td></tr><tr><td>Basophiles [cells/uL]</td><td>0</td><td>0</td><td>0</td><td>0</td><td>0</td><td>0</td><td>0</td><td>0</td><td>0</td></tr><tr><td>Eosinophils [cells/uL]</td><td>808</td><td>0</td><td>0</td><td>100</td><td>112</td><td>216</td><td>148</td><td>285</td><td>0&#x2013;320</td></tr><tr><td>Segmented Neutrophils [cells/uL]</td><td>6060</td><td>
<italic>7800</italic>
</td><td>
<italic>9100</italic>
</td><td>6600</td><td>8736</td><td>6804</td><td>
<italic>11692</italic>
</td><td>5700</td><td>2775&#x2013;7530</td></tr><tr><td>Rod Neutrophils [cells/uL]</td><td>202</td><td>0</td><td>100</td><td>0</td><td>
<italic>448</italic>
</td><td>216</td><td>
<italic>1480</italic>
</td><td>285</td><td>94&#x2013;420</td></tr><tr><td>Lymphocytes [cells/uL]</td><td>2727</td><td>2100</td><td>
<italic>800</italic>
</td><td>2900</td><td>1680</td><td>3348</td><td>1184</td><td>3135</td><td>1088&#x2013;5096</td></tr><tr><td>Monocytes [cells/uL]</td><td>303</td><td>100</td><td>0</td><td>
<italic>400</italic>
</td><td>224</td><td>216</td><td>296</td><td>190</td><td>90&#x2013;318</td></tr><tr><td>Platelets [cells/uL]</td><td>194000</td><td>246000</td><td>242000</td><td>279000</td><td>
<italic>323000</italic>
</td><td>90000</td><td>96000</td><td>
<italic>368000</italic>
</td><td>90000&#x2013;322000</td></tr></tbody></table><table-wrap-foot><p>
<italic>MCV</italic> mean corpuscular volume; <italic>MCH</italic> mean corpuscular hemoglobin; <italic>MCHC</italic> mean corpuscular hemoglobin concentration</p><p>
<sup>a</sup>Reference ranges obtained for total blood cell count for 33 domestic horses of different breeds, serum negative for <italic>Borrelia burgdorferi</italic>, kept under the same feeding and management conditions</p></table-wrap-foot></table-wrap><table-wrap id="Tab2"><label>Table 2</label><caption><p>Gelding blood gas analysis after anaphylactic reaction to sodium ceftriaxone, which occurred on day 1</p></caption><table frame="hsides" rules="groups"><thead><tr><th/><th>Day 2</th><th>Day 3</th><th>Day 28</th><th>Reference<sup>a</sup>
</th></tr></thead><tbody><tr><td>pH</td><td>
<italic>7.271</italic>
</td><td>
<italic>7.467</italic>
</td><td>7.374</td><td>7.384&#x2013;7.408</td></tr><tr><td>pCO<sub>2</sub> [mmHg]</td><td>
<italic>69.6</italic>
</td><td>42.3</td><td>
<italic>45.1</italic>
</td><td>35&#x2013;45</td></tr><tr><td>pO<sub>2</sub> [mmHg]</td><td>
<italic>55.4</italic>
</td><td>38.5</td><td>35</td><td>35&#x2013;45</td></tr><tr><td>HCO<sub>3</sub>
<sup>&#x2212;</sup> [mmol/L]</td><td>
<italic>17.7</italic>
</td><td>27.8</td><td>26.4</td><td>21&#x2013;53</td></tr><tr><td>Na<sup>+</sup> [mmol/L]</td><td>
<italic>116.4</italic>
</td><td>
<italic>130.1</italic>
</td><td>138</td><td>135&#x2013;148</td></tr><tr><td>K<sup>+</sup> [mmol/L]</td><td>
<italic>2.96</italic>
</td><td>
<italic>2.51</italic>
</td><td>4.0</td><td>3.5&#x2013;4.5</td></tr><tr><td>Cl<sup>&#x2212;</sup> [mmol/L]</td><td>
<italic>88.5</italic>
</td><td>100.5</td><td>102.2</td><td>98&#x2013;107</td></tr><tr><td>Glucose [mmol/L]</td><td>
<italic>7.3</italic>
</td><td>
<italic>8.1</italic>
</td><td>4.0</td><td>4.1&#x2013;5.9</td></tr><tr><td>Lactate [mmol/L]</td><td>
<italic>5.6</italic>
</td><td>1.1</td><td>1.2</td><td>1.0&#x2013;1.7</td></tr></tbody></table><table-wrap-foot><p>
<italic>pCO</italic>
<sub><italic>2</italic></sub> partial pressure of carbon dioxide; <italic>pO</italic>
<sub><italic>2</italic></sub> partial pressure of oxygen; <italic>HCO</italic>
<sub><italic>3</italic></sub>
<sup>&#x2212;</sup> bicarbonate ion; <italic>Na</italic>
<sup>+</sup> sodium ion; <italic>K</italic>
<sup>+</sup> potassium ion; <italic>Cl</italic>
<sup>&#x2212;</sup> chloride ion</p><p>
<sup>a</sup>Reference ranges obtained with the iStat EG7+ device</p><p>Values in italic represent relevant modifications in the parameter</p></table-wrap-foot></table-wrap><fig id="Fig1"><label>Fig. 1</label><caption><p>Abdominal ultrasound of the gelding with tympanic colic as a result of anaphylactic reaction to sodium ceftriaxone. Image obtained by ventral-abdominal positioning of the probe, caudal to xiphoid. Note the thickening of intestinal wall, distention, atony and <italic>ileus</italic> in segments of the small intestine. Diagnostic Imaging Sector - FCAV - UNESP - Jaboticabal</p></caption><graphic xlink:href="12917_2015_478_Fig1_HTML" id="MO1"/></fig><fig id="Fig2"><label>Fig. 2</label><caption><p>Exposure of the gelding cecum and jejunum during exploratory celiotomy. Full line arrow: cecum. Dashed line arrow: jejunal serosa showing edema due to anaphylaxis caused by sodium ceftriaxone, in lighter color compared to other intestinal loops</p></caption><graphic xlink:href="12917_2015_478_Fig2_HTML" id="MO2"/></fig><table-wrap id="Tab3"><label>Table 3</label><caption><p>Gelding serum biochemical parameters before and after anaphylactic reaction to sodium ceftriaxone, which occurred on day 1</p></caption><table frame="hsides" rules="groups"><thead><tr><th/><th>Basal</th><th>Day 6</th><th>Day 10</th><th>Day 20</th><th>Day 21</th><th>Day 28</th><th>Reference<sup>a</sup>
</th></tr></thead><tbody><tr><td>Direct bilirubin [mg/dL]</td><td>0.28</td><td>-</td><td>
<italic>1.10</italic>
</td><td>0.29</td><td>
<italic>0.35</italic>
</td><td>0.27</td><td>0.12&#x2013;0.31</td></tr><tr><td>Indirect bilirubin [mg/dL]</td><td>0.06</td><td>-</td><td>0.40</td><td>
<italic>2.25</italic>
</td><td>
<italic>4.12</italic>
</td><td>0.51</td><td>0.07&#x2013;1.07</td></tr><tr><td>Creatine phosphokinase [U/L]</td><td>146</td><td>-</td><td>
<italic>80</italic>
</td><td>
<italic>448</italic>
</td><td>
<italic>1162</italic>
</td><td>120</td><td>84&#x2013;368</td></tr><tr><td>Urea [mg/dL]</td><td>15</td><td>21</td><td>26</td><td>26</td><td>20</td><td>41</td><td>14&#x2013;41</td></tr><tr><td>Creatinine [mg/dL]</td><td>1.3</td><td>1.6</td><td>
<italic>0.9</italic>
</td><td>
<italic>0.9</italic>
</td><td>
<italic>0.7</italic>
</td><td>1.3</td><td>1.1&#x2013;1.7</td></tr><tr><td>Aspartate Amino Transferase [U/L]</td><td>302</td><td>220</td><td>173</td><td>296</td><td>426</td><td>271</td><td>232&#x2013;447</td></tr><tr><td>Gamma Glutamyl Transferase [U/L]</td><td>18</td><td>
<italic>68</italic>
</td><td>
<italic>21</italic>
</td><td>16</td><td>18</td><td>17</td><td>2.0&#x2013;19.0</td></tr><tr><td>Total Protein [g/dL]</td><td>6.4</td><td>6.4</td><td>5.4</td><td>6.9</td><td>
<italic>7.6</italic>
</td><td>6.7</td><td>4.0&#x2013;7.7</td></tr><tr><td>Albumin [g/dL]</td><td>2.4</td><td>-</td><td>2.9</td><td>2.1</td><td>2.3</td><td>1.7</td><td>1.7&#x2013;3.2</td></tr><tr><td>Globulin [g/dL]</td><td>4.0</td><td>-</td><td>2.5</td><td>4.8</td><td>
<italic>5.3</italic>
</td><td>
<italic>5.0</italic>
</td><td>2.3&#x2013;4.8</td></tr><tr><td>Fibrinogen [g/dL]</td><td>0.1</td><td>0.4</td><td>0.5</td><td>
<italic>1.2</italic>
</td><td>
<italic>0.9</italic>
</td><td>0.2</td><td>0.1&#x2013;0.4</td></tr></tbody></table><table-wrap-foot><p>
<sup>a</sup>References ranges obtained from the hematological analysis of 33 domestic horses of several breeds, serum negative for <italic>Borrelia burgdorferi</italic>, kept under the same management and feeding conditions</p><p>Values in italic represent relevant modifications in the parameter</p></table-wrap-foot></table-wrap></p>
      </sec>
      <sec id="Sec4">
        <title>Case 2: Mare</title>
        <p>The Anglo-Arab mare weighing 420&#xA0;kg, submitted to food fasting for 6&#xA0;h, had a basal heart rate (HR) of 38&#xA0;bpm, respiratory rate (RR) of 16 mrm, rosy mucous membranes, capillary refill time (CRT) of 2&#xA0;s, rectal temperature (RT) 36.6&#xA0;&#xB0;C and hematological parameters within the reference range (Table&#xA0;<xref rid="Tab4" ref-type="table">4</xref>, Basal) before starting the antibiotic treatment. After 95&#xA0;mL of the ceftriaxone sodium (Day 1) solution had dripped, the mare presented paresis in the pelvic limbs, suggestive of circulatory hypotension. The antibiotic solution drip was suspended immediately, and within a few minutes, the mare was back to normal with no apparent need for pharmacological intervention. Two days after the anaphylactoid reaction (Day 3), the mare started showing signs of discomfort and slight abdominal distention. The physical examination revealed a HR of 52&#xA0;bpm, RR of 34 mrm, RT 37.5&#xA0;&#xB0;C, CRT 3&#xA0;s, pale mucosa and a severe intestinal hypomotility. No abnormalities were found upon rectal palpation, except for the presence of gas in the bowel loops and wall edema of the rectum. The colic event did not alter the hematological parameters or serum biochemistry of the patient (Tables&#xA0;<xref rid="Tab4" ref-type="table">4</xref> and <xref rid="Tab5" ref-type="table">5</xref>, Day 3). The support treatment consisted of administering 3&#xA0;L of 10&#xA0;% DMSO solution, 10&#xA0;ml intravenous dexamethasone, gastric lavage and100 mL of 30&#xA0;% oral silicon solution to reduce bloating and flunixin meglumine (0.5&#xA0;mg/kg), intravenously. The patient showed improvement in the intestinal motility 6&#xA0;h after the drug treatment had started. Three days after the tympanic colic episode (Day 6), the temperature of the dorsal hoof wall of the left forelimb (LF) increased and the mare revealed strong pulse in the palmar digital arteries (Fig.&#xA0;<xref rid="Fig3" ref-type="fig">3</xref>, Day 6). Cryotherapy was performed in the region between the hoof and carpus for 1 h, three times a day, and intravenous flunixin meglumine, anti-endotoxemic dose (0.25&#xA0;mg/kg), every 12 h. Two days after initiating the cryotherapy (Day 8), no improvement was noted in the LF temperature profile (Fig.&#xA0;<xref rid="Fig4" ref-type="fig">4</xref>). Therefore, along with cryotherapy, firocoxib was administered orally (0.1&#xA0;mg/kg), every 24&#xA0;h, in combination with pentoxifylline (8.4&#xA0;mg/kg), every 12&#xA0;h, for 10&#xA0;days. At the end of the 10th day, the temperature profile of the left forelimb returned to normal values (Fig.&#xA0;<xref rid="Fig3" ref-type="fig">3</xref>, Day 20). The mare showed no signs of pain or lameness in the affected limb at any time; thus, suggesting the development of laminitis was treated within the prodromal phase. Therefore, no hoof radiographic assessment was performed. There were no alterations in the environment or feeding throughout ceftriaxone administration at the beginning of the colic period that would explain the abdominal discomfort occurrence and the resultant laminitis. Therefore, the authors suggest that the possible hypotension was associated with the liberation of inflammatory mediators which caused the subsequent laminitis. Table&#xA0;<xref rid="Tab6" ref-type="table">6</xref> summarizes the events that occurred with the two animals over time. Penicillins are the most important antibiotic class followed by cephalosporins, which contains a beta-lactam ring in their molecular structure. Both groups can induce hypersensitivity reactions mediated by IgE [<xref ref-type="bibr" rid="CR18">18</xref>]. <italic>In vitro</italic> studies demonstrated that IgE antibodies are reactive to both terminals of cephalosporin molecules. This hybridoma formation has shown that cephalosporins can generate unique structures capable of inducing specific allergic reactions, which may exhibit cross-reactivity with penicillin in 5 to 15&#xA0;% of the cases [<xref ref-type="bibr" rid="CR19">19</xref>, <xref ref-type="bibr" rid="CR20">20</xref>]. In this study, both animals had been previously treated with penicillin without any signs of an allergic reaction, which suggests an anaphylactoid reaction. To date, there are no reports regarding the manifestation of hypersensitivity to cephalosporin in horses. This was one of the reasons why a drug of this group (ceftriaxone sodium) was chosen to treat the experimental infection with <italic>Borrelia burgdorferi</italic>. In addition to the cephalosporin pharmacokinetic studies conducted in horses [<xref ref-type="bibr" rid="CR15">15</xref>&#x2013;<xref ref-type="bibr" rid="CR17">17</xref>], clinical trials were also conducted in camels [<xref ref-type="bibr" rid="CR21">21</xref>], dogs [<xref ref-type="bibr" rid="CR22">22</xref>], calves [<xref ref-type="bibr" rid="CR23">23</xref>] and lactating goats [<xref ref-type="bibr" rid="CR24">24</xref>] without any reports regarding the occurrence of hypersensitivity reactions. The evolution of the anaphylactoid symptoms in all of the tried horses was consistent with a severe hypersensitivity reaction in the gelding (without reaching shock parameters) and moderate reaction in the mare, which showed only signs of circulatory hypotension. Typically the symptoms of mild anaphylactoid reactions and hypersensitivity in horses are limited to local and dermatological [<xref ref-type="bibr" rid="CR25">25</xref>, <xref ref-type="bibr" rid="CR26">26</xref>] changes. During a classical anaphylaxis, it is necessary a first substance exposure to immunologic sensitization and a cascade of events associated with the IgE molecule binding to basophils and mast cells occurs, triggering the release of histamine and other vasoactive substances [<xref ref-type="bibr" rid="CR3">3</xref>, <xref ref-type="bibr" rid="CR27">27</xref>], such as serotonin, catecholamines, kinins, products of arachidonic acid and platelet activating factor [<xref ref-type="bibr" rid="CR5">5</xref>]. The anaphylactoid reaction is a non-IgE mediated hypersensitivity response, caused by immune aggregates, complement activation, coagulation activation or autoimmune mechanisms, with the same clinical appearance of a classical anaphylaxis [<xref ref-type="bibr" rid="CR27">27</xref>]. Both horses had never been exposed previously to sodium ceftriaxone and did not have any reaction to penicillin, resulting in an anaphylactoid reaction. Besides, it was not possible to know whether the massive death of spirochetes during antibiotic application also had correlation with clinical signs presented by both horses. Further evidences shall be collected in order to define if the anaphylactoid reaction was caused only by the sodium ceftriaxone or the interaction between the drug and the <italic>B. burgdorferi</italic> infection in horses. The pharmacological treatment with dexamethasone reversed the acute symptoms of the anaphylactoid reaction in the gelding, corroborating published studies [<xref ref-type="bibr" rid="CR9">9</xref>, <xref ref-type="bibr" rid="CR28">28</xref>, <xref ref-type="bibr" rid="CR29">29</xref>]. It has been reported that anti-inflammatory non-steroidal drugs (NSAID&#x2019;s) showed greater efficacy in reversing the cardiovascular and respiratory effects of experimentally induced anaphylaxis in horses compared to antihistamines. Together with corticoids, the animals may also have benefited from epinephrine for controlling acute signs of hypotension and edema [<xref ref-type="bibr" rid="CR25">25</xref>]. The vascular and hemodynamic changes that occurred during reaction in the gelding resulted in a mural edema of various intestinal segments, in addition to <italic>ileus</italic>, with signs of abdominal discomfort. During celiotomy, mural edemas were observed on the colon and small intestine, as well as a large amount of liquid and gaseous content and petechiations promoted by fragility and alteration of vascular permeability. While recovering from the surgical procedure, the gelding erythrogram displayed parameters on the lower limit of normality, neutrophilia with a regenerative left shift or leukopenia (Day 3), which may have been caused by the steroid therapy or anaphylactoid reaction. Along the scenario of metabolic acidosis, there were also electrolyte abnormalities on the day following the anaphylactoid reaction, with decreased plasma concentrations of sodium, potassium and chlorine. The anaphylaxis report where a reaction was induced by intravenous administration of breast milk on a foal lists the same pattern of changes on the following day [<xref ref-type="bibr" rid="CR11">11</xref>]. Such changes can be directly associated to the systemic inflammatory response syndrome induced by the beta lactam compound [<xref ref-type="bibr" rid="CR30">30</xref>]. During an anaphylactoid reaction, large amounts of fluids are sequestered to tissue compartments richer in mast cells and basophils due to antigen-antibody bonds that promote the release of vasoactive amines and hence induce the local vasodilatation. It is known that tissue concentrations (muscle and viscera) of sodium, potassium and chloride increase during anaphylaxis, resulting in a homeostatic imbalance of these serum electrolytes [<xref ref-type="bibr" rid="CR31">31</xref>]. A significant increase in the concentrations of plasma glucose and lactate was also observed, which may be linked to an increased anaerobic metabolism due to difficult tissue gas exchange resulting from the edema. This fact can be explained by the concomitant increase of venous partial pressures of oxygen and carbon dioxide, shown a day after the anaphylactoid reaction in the gelding. Hematologic and metabolic changes may have predisposed the gelding to the appearance of Theileriosis on Day 18. However, the enzymatic biochemical profile of the gelding did not change significantly as a result of anaphylaxis but only after the hemoparasitosis. In the mare, it could be that the anaphylactoid mediators caused the possible hypotension and this may be responsible for starting the systemic inflammatory response that resulted in abdominal discomfort and laminitis (day 6). The inflammatory response was detected by the 10th day, through laboratory confirmation of neutrophilia and increased plasma fibrinogen. The infrared images show apparent temperature increase in the hoof of the left forelimb (day 6), which responded adequately to the non-steroidal anti-inflammatory therapy, cryotherapy and peripheral vasodilator, returning to normal on day 20 post infection.<table-wrap id="Tab4"><label>Table 4</label><caption><p>Mare red blood cell count before and after anaphylactic reaction to sodium ceftriaxone, which occurred on day 1</p></caption><table frame="hsides" rules="groups"><thead><tr><th/><th>Basal</th><th>Day 3</th><th>Day 10</th><th>Day 28</th><th>Reference<sup>a</sup>
</th></tr></thead><tbody><tr><td>Erythrocytes x 10<sup>6</sup> [cells/ml]</td><td>8.3</td><td>7.1</td><td>8.4</td><td>7.4</td><td>6.0&#x2013;9.7</td></tr><tr><td>Hemoglobin [g/dL]</td><td>13</td><td>11.2</td><td>13</td><td>11.5</td><td>8.3&#x2013;14.4</td></tr><tr><td>Hematocrit [%]</td><td>39</td><td>31</td><td>39</td><td>35.0</td><td>30&#x2013;44</td></tr><tr><td>MCV [fL]</td><td>47</td><td>-</td><td>46.4</td><td>47.3</td><td>36&#x2013;52.1</td></tr><tr><td>MCH [pg]</td><td>15.7</td><td>-</td><td>15.5</td><td>15.5</td><td>11.5&#x2013;18.2</td></tr><tr><td>MCHC [g/dL]</td><td>33.3</td><td>-</td><td>33.3</td><td>32.9</td><td>31.2&#x2013;34.9</td></tr><tr><td>Leucocytes [cells/uL]</td><td>8600</td><td>6600</td><td>10000</td><td>6900</td><td>6400&#x2013;10600</td></tr><tr><td>Basophiles [cells/uL]</td><td>0</td><td>0</td><td>0</td><td>0</td><td>0</td></tr><tr><td>Eosinophils [cells/uL]</td><td>
<italic>344</italic>
</td><td>66</td><td>200</td><td>138</td><td>0&#x2013;320</td></tr><tr><td>Segmented Neutrophils [cells/uL]</td><td>4902</td><td>4224</td><td>7300</td><td>3588</td><td>2775&#x2013;7530</td></tr><tr><td>Rod Neutrophils [cells/uL]</td><td>258</td><td>0</td><td>
<italic>800</italic>
</td><td>207</td><td>94&#x2013;420</td></tr><tr><td>Lymphocytes [cells/uL]</td><td>2924</td><td>2244</td><td>1500</td><td>2898</td><td>1088&#x2013;5096</td></tr><tr><td>Monocytes [cells/uL]</td><td>172</td><td>66</td><td>200</td><td>69</td><td>90&#x2013;318</td></tr><tr><td>Platelets [cells/uL]</td><td>151000</td><td>154000</td><td>191000</td><td>165000</td><td>90000&#x2013;322000</td></tr></tbody></table><table-wrap-foot><p>
<sup>a</sup>Reference ranges obtained for total blood cell count for 33 domestic horses of different breeds, serum negative for <italic>Borrelia burgdorferi</italic>, kept under the same feeding and management conditions</p><p>Values in italic represent relevant modifications in the parameter</p></table-wrap-foot></table-wrap><table-wrap id="Tab5"><label>Table 5</label><caption><p>Mare serum biochemical parameters before and after anaphylactic reaction to sodium ceftriaxone, which occurred on day 1</p></caption><table frame="hsides" rules="groups"><thead><tr><th/><th>Basal</th><th>Day 3</th><th>Day 10</th><th>Day 28</th><th>Reference<sup>a</sup>
</th></tr></thead><tbody><tr><td>Direct bilirubin [mg/dL]</td><td>0.13</td><td>0.39</td><td>
<italic>1.1</italic>
</td><td>0.18</td><td>0.12&#x2013;0.31</td></tr><tr><td>Indirect bilirubin [mg/dL]</td><td>0.10</td><td>
<italic>1.66</italic>
</td><td>0.2</td><td>0.63</td><td>0.07&#x2013;1.07</td></tr><tr><td>Creatine phosphokinase [U/L]</td><td>166</td><td>&#x2013;</td><td>276</td><td>223</td><td>84&#x2013;368</td></tr><tr><td>Urea [mg/dL]</td><td>13</td><td>25</td><td>18</td><td>35</td><td>14&#x2013;41</td></tr><tr><td>Creatinine [mg/dL]</td><td>1.1</td><td>1.6</td><td>1.1</td><td>1.0</td><td>1.1&#x2013;1.7</td></tr><tr><td>Aspartate Amino Transferase [U/L]</td><td>424</td><td>199</td><td>263</td><td>368</td><td>232&#x2013;447</td></tr><tr><td>Gamma Glutamyl Transferase [U/L]</td><td>
<italic>33</italic>
</td><td>
<italic>76</italic>
</td><td>
<italic>36</italic>
</td><td>
<italic>23</italic>
</td><td>2.0&#x2013;19.0</td></tr><tr><td>Total Protein [g/dL]</td><td>6.5</td><td>6.4</td><td>6.6</td><td>7.2</td><td>4.0&#x2013;7.7</td></tr><tr><td>Albumin [g/dL]</td><td>2.4</td><td>2.44</td><td>3.4</td><td>2.3</td><td>1.7&#x2013;3.2</td></tr><tr><td>Globulin [g/dL]</td><td>4.1</td><td>-</td><td>3.2</td><td>
<italic>4.9</italic>
</td><td>2.3&#x2013;4.8</td></tr><tr><td>Fibrinogen [g/dL]</td><td>0.1</td><td>0.5</td><td>
<italic>0.9</italic>
</td><td>0.2</td><td>0.1&#x2013;0.4</td></tr></tbody></table><table-wrap-foot><p>
<sup>a</sup>References ranges obtained from the hematological analysis of 33 domestic horses of several breeds, serum negative for <italic>Borrelia burgdorferi</italic>, kept under the same management and feeding conditions</p><p>Values in italic represent relevant modifications in the parameter</p></table-wrap-foot></table-wrap><fig id="Fig3"><label>Fig. 3</label><caption><p>Infrared images to monitor the evolution of the laminitis treatment in the mare that had colic secondary to anaphylactic reactions to ceftriaxone sodium. Day 6 was the second day of temperature rise in the hoof. The crosses indicate the temperature of the hoof crown for each member. Temperature profile of the hooves was back to normal on Day 20. Spot 1: right limb, Spot 2: left limb</p></caption><graphic xlink:href="12917_2015_478_Fig3_HTML" id="MO3"/></fig><fig id="Fig4"><label>Fig. 4</label><caption><p>Infrared image of the four limbs of the mare 2 days after treatment started (Day 8). The crosses indicate the temperature of the hoof crown of each member. Spot 1: right forelimb, Spot 2: left forelimb, Spot 3: right hindlimb, Spot 4: left hindlimb</p></caption><graphic xlink:href="12917_2015_478_Fig4_HTML" id="MO4"/></fig><table-wrap id="Tab6"><label>Table 6</label><caption><p>Timetable of the events described for the anaphylactic reaction to sodium ceftriaxone of a horse and a mare</p></caption><table frame="hsides" rules="groups"><thead><tr><th>Chronology</th><th>Gelding</th><th>Mare</th></tr></thead><tbody><tr><td>Basal</td><td>Total blood cell count before treatment started</td><td>Total blood cell count before treatment started</td></tr><tr><td>Day 1</td><td>Administration of ceftriaxone sodium and anaphylaxis</td><td>Administration of ceftriaxone sodium and anaphylaxis</td></tr><tr><td>Day 2</td><td>Tympanic colic and laparotomy</td><td>Stable</td></tr><tr><td>Day 3</td><td>Stable</td><td>Tympanic colic resolved clinically</td></tr><tr><td>Day 6</td><td>Stable</td><td>Prodromal laminitis and treatment</td></tr><tr><td>Day 8</td><td>Stable</td><td>Change in the laminitis treatment</td></tr><tr><td>Day 18</td><td>Theileriosis treated with imidocarb</td><td>Stable</td></tr><tr><td>Day 20</td><td>6&#xA0;L of whole blood transfusion</td><td>Stabilization of the clinical symptoms</td></tr><tr><td>Day 21</td><td>Gastritis</td><td>Stable</td></tr><tr><td>Day 28</td><td>Clinical symptoms back to normal</td><td>Stable</td></tr></tbody></table></table-wrap></p>
      </sec>
    </sec>
    <sec id="Sec5" sec-type="conclusions">
      <title>Conclusions</title>
      <p>An anaphylactoid reaction is a potential risk to the lives of horses. It is characterized by hypotension and potential cardiovascular collapse, associated with redistribution of the blood volume in the lung and gastrointestinal tract, and may progress to tissue edema and hypertension. Horses that survive these reactions may develop a number of complications, including colic syndrome, laminitis and manifestation of latent infectious diseases.</p>
    </sec>
  </body>
  <back>
    <glossary>
      <title>Abbreviations</title>
      <def-list>
        <def-item>
          <term>C3A</term>
          <def>
            <p>Complement componnet 3A</p>
          </def>
        </def-item>
        <def-item>
          <term>C567</term>
          <def>
            <p>Complement components 5, 6 and 7</p>
          </def>
        </def-item>
        <def-item>
          <term>C5A</term>
          <def>
            <p>Complement component 5A</p>
          </def>
        </def-item>
        <def-item>
          <term>CEUA</term>
          <def>
            <p>Comit&#xEA; de &#xC9;tica e Uso Animal</p>
          </def>
        </def-item>
        <def-item>
          <term>CRT</term>
          <def>
            <p>Capilary refil time</p>
          </def>
        </def-item>
        <def-item>
          <term>dL</term>
          <def>
            <p>Deciliter</p>
          </def>
        </def-item>
        <def-item>
          <term>DMSO</term>
          <def>
            <p>Dimetil sulfoxide</p>
          </def>
        </def-item>
        <def-item>
          <term>FAPESP</term>
          <def>
            <p>Funda&#xE7;&#xE3;o de Ampoaro e Apoi &#xE0; Pesquisa do Estado de SP</p>
          </def>
        </def-item>
        <def-item>
          <term>g</term>
          <def>
            <p>Gram</p>
          </def>
        </def-item>
        <def-item>
          <term>HR</term>
          <def>
            <p>Heart hate</p>
          </def>
        </def-item>
        <def-item>
          <term>IgE</term>
          <def>
            <p>Imunoglobulin E</p>
          </def>
        </def-item>
        <def-item>
          <term>kg</term>
          <def>
            <p>Kilogram</p>
          </def>
        </def-item>
        <def-item>
          <term>L</term>
          <def>
            <p>Liter</p>
          </def>
        </def-item>
        <def-item>
          <term>LF</term>
          <def>
            <p>Left forelimb</p>
          </def>
        </def-item>
        <def-item>
          <term>LH</term>
          <def>
            <p>Left hindlimb</p>
          </def>
        </def-item>
        <def-item>
          <term>MCH</term>
          <def>
            <p>Mean corpuscular hemoglobin</p>
          </def>
        </def-item>
        <def-item>
          <term>MCHC</term>
          <def>
            <p>Mean corpuscular hemoglobin concentration</p>
          </def>
        </def-item>
        <def-item>
          <term>MCV</term>
          <def>
            <p>Mean corpuscular volume</p>
          </def>
        </def-item>
        <def-item>
          <term>mg</term>
          <def>
            <p>Milligram</p>
          </def>
        </def-item>
        <def-item>
          <term>MG</term>
          <def>
            <p>Minas Gerais</p>
          </def>
        </def-item>
        <def-item>
          <term>NSAID</term>
          <def>
            <p>Non steroidal anti-inflamatory drugs</p>
          </def>
        </def-item>
        <def-item>
          <term>PCR</term>
          <def>
            <p>Polymerase Chain Reaction</p>
          </def>
        </def-item>
        <def-item>
          <term>RF</term>
          <def>
            <p>Right forelimb</p>
          </def>
        </def-item>
        <def-item>
          <term>RH</term>
          <def>
            <p>Right hindlimb</p>
          </def>
        </def-item>
        <def-item>
          <term>RJ</term>
          <def>
            <p>Rio de Janeiro</p>
          </def>
        </def-item>
        <def-item>
          <term>RR</term>
          <def>
            <p>Respiratory rate</p>
          </def>
        </def-item>
        <def-item>
          <term>RT</term>
          <def>
            <p>Retal temperature</p>
          </def>
        </def-item>
        <def-item>
          <term>s</term>
          <def>
            <p>Second</p>
          </def>
        </def-item>
        <def-item>
          <term>SP</term>
          <def>
            <p>S&#xE3;o Paulo</p>
          </def>
        </def-item>
        <def-item>
          <term>U</term>
          <def>
            <p>Units</p>
          </def>
        </def-item>
        <def-item>
          <term>UNESP</term>
          <def>
            <p>Universidade Estadual Paulista</p>
          </def>
        </def-item>
      </def-list>
    </glossary>
    <fn-group>
      <fn id="Fn1">
        <label>1</label>
        <p>Celltriaxon&#xAE;, Agila Especialidades Farmac&#xEA;uticas, Campos dos Goytacazes &#x2013; RJ &#x2013; Brazil. Batch: 7402209. Manufacture: 10/2013. Validity: 10/2015.</p>
      </fn>
      <fn id="Fn2">
        <label>2</label>
        <p>Angiocath&#xAE; 14G, BD, S&#xE3;o Paulo &#x2013; Brazil.</p>
      </fn>
      <fn id="Fn3">
        <label>3</label>
        <p>Novapen&#xAE; &#x2013; Hertape Calier, Juatuba &#x2013; MG.</p>
      </fn>
      <fn id="Fn4">
        <label>4</label>
        <p>Imizol&#xAE; &#x2013; MSD Sa&#xFA;de Animal, S&#xE3;o Paulo &#x2013; SP.</p>
      </fn>
      <fn id="Fn5">
        <label>5</label>
        <p>Gastrozol&#xAE; 2.28g &#x2013; Hertape Calier, Juatuba &#x2013; MG.</p>
      </fn>
      <fn>
        <p>
          <bold>Competing interests</bold>
        </p>
        <p>The authors declare that they have no competing interests.</p>
      </fn>
      <fn>
        <p>
          <bold>Authors&#x2019; contributions</bold>
        </p>
        <p>RCB and AQN designed and planned the experiment. RCB, GGR, THIEF, TCMB, GPDA, EG, GCF, AQN and PAC executed the experimental and clinical procedures. RCB and AQN drafted the manuscript. All authors read and approved the manuscript.</p>
      </fn>
    </fn-group>
    <ack>
      <title>Acknowledgements</title>
      <p>The authors acknowledge the financial support of FAPESP (Process 2013/2013 and 05871-0/03732-0). The authors also thank the valuable contribution to the therapeutic monitoring of both animals during the reported event: Aline Silva Tempesta, Luciana Leon Scrivano, Flora D'Angelis de Freitas, Helena Cristina Brito Delgado, Jessica Lage, Julia Garcia de Carvalho, Yuri da Silva Bonaccin and Vanessa Barroco de Paula.</p>
    </ack>
    <ref-list id="Bib1">
      <title>References</title>
      <ref id="CR1">
        <label>1.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Butler</surname>
              <given-names>CM</given-names>
            </name>
            <name>
              <surname>Houwers</surname>
              <given-names>DJ</given-names>
            </name>
            <name>
              <surname>Jongejan</surname>
              <given-names>F</given-names>
            </name>
            <name>
              <surname>Van der Kolk</surname>
              <given-names>JH</given-names>
            </name>
          </person-group>
          <article-title><italic>Borrelia burgdorferi</italic> infections with special reference to horses. A review</article-title>
          <source>Vet. Q.</source>
          <year>2005</year>
          <volume>27</volume>
          <fpage>146</fpage>
          <lpage>156</lpage>
          <pub-id pub-id-type="doi">10.1080/01652176.2002.9695196</pub-id>
          <pub-id pub-id-type="pmid">16402512</pub-id>
        </element-citation>
      </ref>
      <ref id="CR2">
        <label>2.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Stanek</surname>
              <given-names>G</given-names>
            </name>
            <name>
              <surname>Wormser</surname>
              <given-names>GP</given-names>
            </name>
            <name>
              <surname>Gray</surname>
              <given-names>J</given-names>
            </name>
            <name>
              <surname>Strle</surname>
              <given-names>F</given-names>
            </name>
          </person-group>
          <article-title>Lyme borreliosis</article-title>
          <source>Lancet</source>
          <year>2012</year>
          <volume>379</volume>
          <fpage>461</fpage>
          <lpage>473</lpage>
          <pub-id pub-id-type="doi">10.1016/S0140-6736(11)60103-7</pub-id>
          <pub-id pub-id-type="pmid">21903253</pub-id>
        </element-citation>
      </ref>
      <ref id="CR3">
        <label>3.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Voehringer</surname>
              <given-names>D</given-names>
            </name>
          </person-group>
          <article-title>Protective and pathological roles of mast cells and basophils</article-title>
          <source>Nat. Rev. Immunol.</source>
          <year>2013</year>
          <volume>13</volume>
          <fpage>362</fpage>
          <lpage>375</lpage>
          <pub-id pub-id-type="doi">10.1038/nri3427</pub-id>
          <pub-id pub-id-type="pmid">23558889</pub-id>
        </element-citation>
      </ref>
      <ref id="CR4">
        <label>4.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Estelle</surname>
              <given-names>F</given-names>
            </name>
            <name>
              <surname>Simons</surname>
              <given-names>R</given-names>
            </name>
          </person-group>
          <article-title>Anaphylaxis</article-title>
          <source>J. Allergy Clin. Immunol.</source>
          <year>2010</year>
          <volume>125</volume>
          <fpage>s161</fpage>
          <lpage>s181</lpage>
          <pub-id pub-id-type="doi">10.1016/j.jaci.2009.12.981</pub-id>
          <pub-id pub-id-type="pmid">20176258</pub-id>
        </element-citation>
      </ref>
      <ref id="CR5">
        <label>5.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Eyre</surname>
              <given-names>P</given-names>
            </name>
          </person-group>
          <article-title>Pharmacological aspects of hypersensitivity in domestic animals: A review</article-title>
          <source>Vet Res Commun</source>
          <year>1980</year>
          <volume>4</volume>
          <fpage>83</fpage>
          <lpage>98</lpage>
          <pub-id pub-id-type="doi">10.1007/BF02278485</pub-id>
        </element-citation>
      </ref>
      <ref id="CR6">
        <label>6.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Chand</surname>
              <given-names>N</given-names>
            </name>
            <name>
              <surname>Eyre</surname>
              <given-names>P</given-names>
            </name>
          </person-group>
          <article-title>Nonsteroidal anti-inflammatory drugs: A review. New applications in hypersensitivity reactions in cattle and horses</article-title>
          <source>Can. J. Comp. Med.</source>
          <year>1977</year>
          <volume>41</volume>
          <fpage>233</fpage>
          <lpage>240</lpage>
          <pub-id pub-id-type="pmid">332290</pub-id>
        </element-citation>
      </ref>
      <ref id="CR7">
        <label>7.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Lagopoulos</surname>
              <given-names>V</given-names>
            </name>
            <name>
              <surname>Gigi</surname>
              <given-names>E</given-names>
            </name>
          </person-group>
          <article-title>Anaphylactic and anaphylactoid reactions during perioperative period</article-title>
          <source>Hippokratia</source>
          <year>2011</year>
          <volume>15</volume>
          <fpage>138</fpage>
          <lpage>140</lpage>
          <pub-id pub-id-type="pmid">22110295</pub-id>
        </element-citation>
      </ref>
      <ref id="CR8">
        <label>8.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Eyre</surname>
              <given-names>P</given-names>
            </name>
            <name>
              <surname>Lewis</surname>
              <given-names>AJ</given-names>
            </name>
          </person-group>
          <article-title>Acute systemic anaphylaxis in the horse</article-title>
          <source>Br J Pharmacol</source>
          <year>1973</year>
          <volume>48</volume>
          <fpage>426</fpage>
          <lpage>437</lpage>
          <pub-id pub-id-type="doi">10.1111/j.1476-5381.1973.tb08351.x</pub-id>
          <pub-id pub-id-type="pmid">4764291</pub-id>
        </element-citation>
      </ref>
      <ref id="CR9">
        <label>9.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Eyre</surname>
              <given-names>P</given-names>
            </name>
          </person-group>
          <article-title>Preliminary studies of pharmacological antagonism of anaphylaxis in the horse</article-title>
          <source>Can. J. Comp. Med.</source>
          <year>1976</year>
          <volume>40</volume>
          <fpage>149</fpage>
          <lpage>152</lpage>
          <pub-id pub-id-type="pmid">1033778</pub-id>
        </element-citation>
      </ref>
      <ref id="CR10">
        <label>10.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Breukink</surname>
              <given-names>HJ</given-names>
            </name>
            <name>
              <surname>Eysker</surname>
              <given-names>M</given-names>
            </name>
          </person-group>
          <article-title>Intravenous administration of Ivomec in horses</article-title>
          <source>Tijdschr Diergeneeskd</source>
          <year>1995</year>
          <volume>120</volume>
          <fpage>113</fpage>
          <lpage>114</lpage>
          <pub-id pub-id-type="pmid">7863483</pub-id>
        </element-citation>
      </ref>
      <ref id="CR11">
        <label>11.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Alcott</surname>
              <given-names>CJ</given-names>
            </name>
            <name>
              <surname>Wong</surname>
              <given-names>DM</given-names>
            </name>
          </person-group>
          <article-title>Anaphylaxis and systemic inflammatory response syndrome induced by inadvertent intravenous administration of mare&#x2019;s milk in an neonatal foal</article-title>
          <source>J Vet Emerg Crit Care</source>
          <year>2010</year>
          <volume>20</volume>
          <fpage>616</fpage>
          <lpage>622</lpage>
          <pub-id pub-id-type="doi">10.1111/j.1476-4431.2010.00586.x</pub-id>
        </element-citation>
      </ref>
      <ref id="CR12">
        <label>12.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Fadok</surname>
              <given-names>VA</given-names>
            </name>
          </person-group>
          <article-title>Update on equine allergies</article-title>
          <source>Vet. Clin. N. Am. Equine Pract.</source>
          <year>2013</year>
          <volume>29</volume>
          <fpage>541</fpage>
          <lpage>550</lpage>
          <pub-id pub-id-type="doi">10.1016/j.cveq.2013.08.005</pub-id>
        </element-citation>
      </ref>
      <ref id="CR13">
        <label>13.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Wagner</surname>
              <given-names>B</given-names>
            </name>
          </person-group>
          <article-title>IgE in horses: Occurrence in health and disease</article-title>
          <source>Vet. Immunol. Immunopathol.</source>
          <year>2009</year>
          <volume>132</volume>
          <fpage>21</fpage>
          <lpage>30</lpage>
          <pub-id pub-id-type="doi">10.1016/j.vetimm.2009.09.011</pub-id>
          <pub-id pub-id-type="pmid">19819562</pub-id>
        </element-citation>
      </ref>
      <ref id="CR14">
        <label>14.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Halperin</surname>
              <given-names>JJ</given-names>
            </name>
          </person-group>
          <article-title>Nervous system Lyme disease</article-title>
          <source>Handb. Clin. Neurol.</source>
          <year>2014</year>
          <volume>121</volume>
          <fpage>1473</fpage>
          <lpage>1483</lpage>
          <pub-id pub-id-type="doi">10.1016/B978-0-7020-4088-7.00099-7</pub-id>
          <pub-id pub-id-type="pmid">24365431</pub-id>
        </element-citation>
      </ref>
      <ref id="CR15">
        <label>15.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Gardner</surname>
              <given-names>SY</given-names>
            </name>
            <name>
              <surname>Aucoin</surname>
              <given-names>DP</given-names>
            </name>
          </person-group>
          <article-title>Pharmacokinetics of ceftriaxone in mares</article-title>
          <source>J Vet Pharmacol Ther</source>
          <year>1994</year>
          <volume>17</volume>
          <fpage>155</fpage>
          <lpage>156</lpage>
          <pub-id pub-id-type="doi">10.1111/j.1365-2885.1994.tb00226.x</pub-id>
          <pub-id pub-id-type="pmid">8040935</pub-id>
        </element-citation>
      </ref>
      <ref id="CR16">
        <label>16.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Ringger</surname>
              <given-names>NC</given-names>
            </name>
            <name>
              <surname>Pearson</surname>
              <given-names>EG</given-names>
            </name>
            <name>
              <surname>Gronwall</surname>
              <given-names>R</given-names>
            </name>
            <name>
              <surname>Kolepp</surname>
              <given-names>SJ</given-names>
            </name>
          </person-group>
          <article-title>Pharmacokinetics of ceftriaxone in healthy horses</article-title>
          <source>Equine Vet J</source>
          <year>1996</year>
          <volume>28</volume>
          <fpage>476</fpage>
          <lpage>479</lpage>
          <pub-id pub-id-type="doi">10.1111/j.2042-3306.1996.tb01620.x</pub-id>
          <pub-id pub-id-type="pmid">9049497</pub-id>
        </element-citation>
      </ref>
      <ref id="CR17">
        <label>17.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Ringger</surname>
              <given-names>NC</given-names>
            </name>
            <name>
              <surname>Brown</surname>
              <given-names>MP</given-names>
            </name>
            <name>
              <surname>Kohlepp</surname>
              <given-names>SJ</given-names>
            </name>
            <name>
              <surname>Gronwall</surname>
              <given-names>RR</given-names>
            </name>
            <name>
              <surname>Merritt</surname>
              <given-names>K</given-names>
            </name>
          </person-group>
          <article-title>Pharmacokinetics of ceftriaxone in neonatal foals</article-title>
          <source>Equine Vet J</source>
          <year>1998</year>
          <volume>30</volume>
          <fpage>163</fpage>
          <lpage>165</lpage>
          <pub-id pub-id-type="doi">10.1111/j.2042-3306.1998.tb04477.x</pub-id>
          <pub-id pub-id-type="pmid">9535074</pub-id>
        </element-citation>
      </ref>
      <ref id="CR18">
        <label>18.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Romano</surname>
              <given-names>A</given-names>
            </name>
            <name>
              <surname>Gaeta</surname>
              <given-names>F</given-names>
            </name>
            <name>
              <surname>Valluzi</surname>
              <given-names>RL</given-names>
            </name>
            <name>
              <surname>Caruso</surname>
              <given-names>C</given-names>
            </name>
            <name>
              <surname>Rumi</surname>
              <given-names>G</given-names>
            </name>
            <name>
              <surname>Bousquet</surname>
              <given-names>PJ</given-names>
            </name>
          </person-group>
          <article-title>IgE-mediated hypersensitivity to cephalosporins: Cross-reactivity and tolerability of penicilins, monobactams and carbapenems</article-title>
          <source>J Allergy Clin Immunol</source>
          <year>2010</year>
          <volume>126</volume>
          <fpage>994</fpage>
          <lpage>999</lpage>
          <pub-id pub-id-type="doi">10.1016/j.jaci.2010.06.052</pub-id>
          <pub-id pub-id-type="pmid">20888035</pub-id>
        </element-citation>
      </ref>
      <ref id="CR19">
        <label>19.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Pham</surname>
              <given-names>NH</given-names>
            </name>
            <name>
              <surname>Baldo</surname>
              <given-names>BA</given-names>
            </name>
          </person-group>
          <article-title>Beta-lactam drug allergens. Fine structural recognition patterns of cephalosporin-reactive IgE antibodies</article-title>
          <source>J Mol Recognit</source>
          <year>1996</year>
          <volume>9</volume>
          <fpage>287</fpage>
          <lpage>296</lpage>
          <pub-id pub-id-type="doi">10.1002/(SICI)1099-1352(199607)9:4&lt;287::AID-JMR340&gt;3.0.CO;2-L</pub-id>
          <pub-id pub-id-type="pmid">9131470</pub-id>
        </element-citation>
      </ref>
      <ref id="CR20">
        <label>20.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Baldo</surname>
              <given-names>BA</given-names>
            </name>
          </person-group>
          <article-title>Penicillins and cephalosporins as allergens &#x2013; structural aspects of recognition and cross-reactions</article-title>
          <source>Clin. Exp. Allergy</source>
          <year>1999</year>
          <volume>29</volume>
          <fpage>744</fpage>
          <lpage>749</lpage>
          <pub-id pub-id-type="doi">10.1046/j.1365-2222.1999.00575.x</pub-id>
          <pub-id pub-id-type="pmid">10336588</pub-id>
        </element-citation>
      </ref>
      <ref id="CR21">
        <label>21.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Goudah</surname>
              <given-names>A</given-names>
            </name>
          </person-group>
          <article-title>Pharmacokinetic parameters of ceftriaxone after single intravenous and intramuscular administration in camels (<italic>Camelus Dromedarius</italic>)</article-title>
          <source>Res Vet Sci</source>
          <year>2008</year>
          <volume>84</volume>
          <fpage>483</fpage>
          <lpage>489</lpage>
          <pub-id pub-id-type="doi">10.1016/j.rvsc.2007.07.005</pub-id>
          <pub-id pub-id-type="pmid">17765938</pub-id>
        </element-citation>
      </ref>
      <ref id="CR22">
        <label>22.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Rebuelto</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Albarellos</surname>
              <given-names>G</given-names>
            </name>
            <name>
              <surname>Ambros</surname>
              <given-names>L</given-names>
            </name>
            <name>
              <surname>Kreil</surname>
              <given-names>V</given-names>
            </name>
            <name>
              <surname>Montoya</surname>
              <given-names>L</given-names>
            </name>
            <name>
              <surname>Bonafine</surname>
              <given-names>R</given-names>
            </name>
            <name>
              <surname>Otero</surname>
              <given-names>P</given-names>
            </name>
            <name>
              <surname>Hallu</surname>
              <given-names>R</given-names>
            </name>
          </person-group>
          <article-title>Pharmacokinetics of ceftriaxone administered by intravenous, intramuscular or subcutaneous routes in dogs</article-title>
          <source>J. Vet. Pharmacol. Ther.</source>
          <year>2002</year>
          <volume>25</volume>
          <fpage>73</fpage>
          <lpage>76</lpage>
          <pub-id pub-id-type="doi">10.1046/j.1365-2885.2002.00389.x</pub-id>
          <pub-id pub-id-type="pmid">11874531</pub-id>
        </element-citation>
      </ref>
      <ref id="CR23">
        <label>23.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Maradiya</surname>
              <given-names>JJ</given-names>
            </name>
            <name>
              <surname>Goriya</surname>
              <given-names>HV</given-names>
            </name>
            <name>
              <surname>Bhavsar</surname>
              <given-names>SK</given-names>
            </name>
            <name>
              <surname>Patel</surname>
              <given-names>UD</given-names>
            </name>
            <name>
              <surname>Thaker</surname>
              <given-names>AM</given-names>
            </name>
          </person-group>
          <article-title>Pharmacokinetics of ceftriaxone in calves</article-title>
          <source>Veterinarski Arhiv</source>
          <year>2010</year>
          <volume>80</volume>
          <fpage>1</fpage>
          <lpage>9</lpage>
        </element-citation>
      </ref>
      <ref id="CR24">
        <label>24.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Ismail</surname>
              <given-names>MM</given-names>
            </name>
          </person-group>
          <article-title>Pharmacokinetics, urinary and mammary excretion of ceftriaxone in lactating goats</article-title>
          <source>J Veterinary Med Ser A</source>
          <year>2005</year>
          <volume>52</volume>
          <fpage>354</fpage>
          <lpage>358</lpage>
          <pub-id pub-id-type="doi">10.1111/j.1439-0442.2005.00744.x</pub-id>
        </element-citation>
      </ref>
      <ref id="CR25">
        <label>25.</label>
        <element-citation publication-type="book">
          <person-group person-group-type="author">
            <name>
              <surname>Orsini</surname>
              <given-names>JA</given-names>
            </name>
            <name>
              <surname>Divers</surname>
              <given-names>TJ</given-names>
            </name>
          </person-group>
          <source>Equine emergencies: Treatment and Procedures &#x2013; Third Edition</source>
          <year>2013</year>
          <publisher-loc>St. Louis, EUA</publisher-loc>
          <publisher-name>Elseviers Saunders</publisher-name>
        </element-citation>
      </ref>
      <ref id="CR26">
        <label>26.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Swiderski</surname>
              <given-names>CE</given-names>
            </name>
          </person-group>
          <article-title>Hypersensitivity disorders in horses</article-title>
          <source>Vet. Clin. N. Am. Equine Pract.</source>
          <year>2000</year>
          <volume>16</volume>
          <fpage>131</fpage>
          <lpage>151</lpage>
        </element-citation>
      </ref>
      <ref id="CR27">
        <label>27.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Peters</surname>
              <given-names>LJ</given-names>
            </name>
            <name>
              <surname>Kovacic</surname>
              <given-names>JP</given-names>
            </name>
          </person-group>
          <article-title>Histamine: metabolism, phisiology, and pathophysiology with applications in veterinary medicine</article-title>
          <source>Journal of Emergency and Critical Care</source>
          <year>2009</year>
          <volume>19</volume>
          <fpage>311</fpage>
          <lpage>328</lpage>
          <pub-id pub-id-type="doi">10.1111/j.1476-4431.2009.00434.x</pub-id>
        </element-citation>
      </ref>
      <ref id="CR28">
        <label>28.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Eyre</surname>
              <given-names>P</given-names>
            </name>
            <name>
              <surname>Hanna</surname>
              <given-names>CJ</given-names>
            </name>
            <name>
              <surname>Wells</surname>
              <given-names>PW</given-names>
            </name>
            <name>
              <surname>Mcbeath</surname>
              <given-names>DG</given-names>
            </name>
          </person-group>
          <article-title>Equine immunology 3: Immunopharmacology &#x2013; Anti-inflammatory and antihypersensitivity drugs</article-title>
          <source>Equine Vet J</source>
          <year>1982</year>
          <volume>14</volume>
          <issue>4</issue>
          <fpage>277</fpage>
          <lpage>281</lpage>
          <pub-id pub-id-type="doi">10.1111/j.2042-3306.1982.tb02424.x</pub-id>
          <pub-id pub-id-type="pmid">6129136</pub-id>
        </element-citation>
      </ref>
      <ref id="CR29">
        <label>29.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Hanna</surname>
              <given-names>CJ</given-names>
            </name>
            <name>
              <surname>Eyre</surname>
              <given-names>P</given-names>
            </name>
            <name>
              <surname>Wells</surname>
              <given-names>PW</given-names>
            </name>
            <name>
              <surname>Mcbeat</surname>
              <given-names>DG</given-names>
            </name>
          </person-group>
          <article-title>Equine immunology 2: Immunopharmacology &#x2013; Biochemical basis of hypersensitivity</article-title>
          <source>Equine Vet J</source>
          <year>1982</year>
          <volume>14</volume>
          <fpage>16</fpage>
          <lpage>24</lpage>
          <pub-id pub-id-type="doi">10.1111/j.2042-3306.1982.tb02328.x</pub-id>
          <pub-id pub-id-type="pmid">7044780</pub-id>
        </element-citation>
      </ref>
      <ref id="CR30">
        <label>30.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Hoorn</surname>
              <given-names>EJ</given-names>
            </name>
            <name>
              <surname>Zietse</surname>
              <given-names>R</given-names>
            </name>
          </person-group>
          <article-title>Severe hypokalaemia caused by flucloxacillin</article-title>
          <source>J. Antimicrob. Chemother.</source>
          <year>2008</year>
          <volume>61</volume>
          <issue>6</issue>
          <fpage>1396</fpage>
          <lpage>8</lpage>
          <pub-id pub-id-type="doi">10.1093/jac/dkn117</pub-id>
          <pub-id pub-id-type="pmid">18388113</pub-id>
        </element-citation>
      </ref>
      <ref id="CR31">
        <label>31.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Einbinder</surname>
              <given-names>JM</given-names>
            </name>
            <name>
              <surname>Nelson</surname>
              <given-names>CT</given-names>
            </name>
            <name>
              <surname>Fox</surname>
              <given-names>CL</given-names>
              <suffix>Jr</suffix>
            </name>
          </person-group>
          <article-title>Tissue electrolyte changes in anaphylactic shock</article-title>
          <source>Am J Physiol</source>
          <year>1954</year>
          <volume>179</volume>
          <fpage>347</fpage>
          <lpage>352</lpage>
          <pub-id pub-id-type="pmid">13218172</pub-id>
        </element-citation>
      </ref>
    </ref-list>
  </back>
</article>
</pmc-articleset>
